Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linagliptin add-on therapy in elderly patients with type 2 diabetes mellitus
NL-OMON34800Phase 3Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Linagliptin add-on with Placebo add-on (2 arms). Primary endpoints: Change in HbA1c at 24 weeks and Safety and tolerability. Started Mar 2010; status: recruiting.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON34800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34800.